TY - JOUR
T1 - Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i
AU - Singer, Susanne
AU - Arraras, Juan I.
AU - Baumann, Ingo
AU - Boehm, Andreas
AU - Chie, Wei Chu
AU - Galalae, Razvan
AU - Langendijk, Johannes A.
AU - Guntinas-Lichius, Orlando
AU - Hammerlid, Eva
AU - Pinto, Monica
AU - Nicolatou-Galitis, Ourania
AU - Schmalz, Claudia
AU - Sen, Mehmet
AU - Sherman, Allen C.
AU - Spiegel, Karin
AU - Verdonck-De Leeuw, Irma
AU - Yarom, Noam
AU - Zotti, Paola
AU - Hofmeister, Dirk
PY - 2013/9
Y1 - 2013/9
N2 - Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.
AB - Background The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. Methods The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. Results Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. Conclusions Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.
KW - chemoradiation
KW - head and neck neoplasms
KW - larynx
KW - multimodal therapies
KW - oral cavity
KW - pharynx
UR - http://www.scopus.com/inward/record.url?scp=84883051141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883051141&partnerID=8YFLogxK
U2 - 10.1002/hed.23127
DO - 10.1002/hed.23127
M3 - Article
C2 - 22907791
AN - SCOPUS:84883051141
VL - 35
SP - 1331
EP - 1338
JO - Head and Neck Surgery
JF - Head and Neck Surgery
SN - 1043-3074
IS - 9
ER -